Steven Cohen (Trades, Portfolio), through Point72 Asset Management, has recently made a notable adjustment in the firm's investment portfolio by reducing its stake in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This trade has altered the firm's portfolio by a -0.09% impact, with CRNX now representing 0.36% of the total portfolio and 5.10% of the firm's holdings in the traded stock.
Steven Cohen (Trades, Portfolio)'s investment firm, Point72, has recently expanded its portfolio by adding shares of PagSeguro Digital Ltd (NYSE:PAGS), a prominent financial technology company based in Brazil. On December 31, 2023, Point72 acquired 10,933,610 shares of PagSeguro Digital, reflecting a notable investment move in the tech sector.
Strategic Portfolio Addition Glenn Greenberg (Trades, Portfolio)'s investment firm, Brave Warrior Advisors, has recently increased its investment in OneMain Holdings Inc (NYSE:OMF), a prominent player in the nonprime consumer finance sector in the United States. Following the trade, Brave Warrior Advisors holds a total of 6,416,800 shares in OneMain Holdings Inc, which represents 7.77% of the firm's portfolio and 5.36% of the company's outstanding shares. Glenn Greenberg (Trades, Portfolio)'s Investment Approach Glenn Greenberg (Trades, Portfolio), a notable figure in the investment community, co-founded Chieftain Capital Management in 1984 and later spearheaded Brave Warrior Advisors.
Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently made a notable adjustment in its investment portfolio by reducing its stake in First Financial Northwest Inc (NASDAQ:FFNW). Following this transaction, Renaissance Technologies holds a total of 486,801 shares in the company, which represents a 5.30% ownership and a minimal 0.01% position in the firm's portfolio, indicating a relatively small trade impact.
Overview of Jim Simons (Trades, Portfolio)'s Latest Portfolio Addition Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently expanded its investment portfolio with the acquisition of 3,681,125 shares in Vanda Pharmaceuticals Inc (NASDAQ:VNDA). With a trade price of $4.22 per share, the firm has demonstrated a strategic interest in the biopharmaceutical sector, marking a new investment direction with potential growth opportunities.